FIELD: medicine.
SUBSTANCE: invention relates to a method for prediction of risk of respiratory failure in a septic patient. Method comprises a step of measuring concentration of endocan in blood sample, obtained from said septic patient, and a step for comparing concentration of endocan with preset threshold values, which are measured at average concentration in patients without developed respiratory failure. At concentration lower than a predetermined value, a respiratory failure 48-72 hours after admission of patients suffering sepsis in OIT is predicted.
EFFECT: use of disclosed method enables higher effectiveness of prediction of risk of developing respiratory failure in septic patient.
1 cl, 4 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR APPLICATION IN TREATMENT OF LESIONAL VESTIBULAR DISORDERS | 2010 |
|
RU2608458C2 |
| METHOD FOR PREDICTING SEVERE RESPIRATORY FAILURE IN NEWBORNS BORN TO MOTHERS WITH PREECLAMPSIA | 2020 |
|
RU2751287C1 |
| USE OF LEVOCETIRIZINE AND MONTELUKAST IN TREATMENT OF TRAUMATIC INJURY | 2014 |
|
RU2672871C2 |
| PROADM FOR PREDICTING RISK OF CONDITION REQUIRING HOSPITALIZATION IN PATIENTS WITH SYMPTOMS OF INFECTIOUS DISEASE | 2019 |
|
RU2820944C2 |
| METHOD OF TREATMENT OF CHILDREN WITH RESPIRATORY INSUFFICIENCY AT CRITICAL STATES | 1999 |
|
RU2149017C1 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF KIDNEY CANCER | 2017 |
|
RU2752322C2 |
| METHODS AND APPLICATIONS OF INHIBITORS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN, TYPE 9 (PCSK9) | 2013 |
|
RU2636820C2 |
| HISTONES AND/OR proADM AS MARKERS TESTIFYING ABOUT ORGAN DYSFUNCTION | 2017 |
|
RU2764766C2 |
| METHODS FOR PATIENT'S RESPONSE TO HOSPITAL INFECTION TEST AND FORECASTING OF DEVELOPING SEPSIS SYNDROME | 2010 |
|
RU2525707C2 |
